Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Cytarabine 7Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4Methotrexate 4fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Melphalan 3Daunorubicin 3Cyclosporine 3Asparaginase 3merphos 2Thioguanine 2Patient Reported Outcome Measures 2Mitoxantrone 2Mesna 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Bone Marrow Transplantation 2Azacitidine 2Antilymphocyte Serum 2zosuquidar trihydrochloride 1treosulfan 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Myelodysplastic Syndromes × Leyk × Clear all
NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Children's Oncology Group

Phase 3 Active not recruiting
280 enrolled 13 charts
MyeloidOther hematologic neoplasm

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡